關於 silmitasertib ，我們在網路上蒐集到這些相關的討論、資訊與評價

#11. Silmitasertib | C19H12ClN3O2 - PubChem

Silmitasertib is an orally bioavailable small-molecule inhibitor of the enzyme casein kinase II (CK2), with potential antineoplastic, anti-viral and ...

#12. 生華科新藥Silmitasertib 抗疫露曙光證實有效抑制冠狀病毒 ...

生華科昨 (21) 日宣布，旗下新藥Silmitasertib(CX-4945)委由台灣國衛院冠狀病毒篩選平台，進行人類流感冠狀病毒體外試驗，試驗結果證實，Silmitasertib 具有良好抑制 ...

#13. Silmitasertib - Wikipedia

Silmitasertib (INN), codenamed CX-4945, is a small-molecule inhibitor of protein kinase CK2 (casein kinase II), a constitutively active ...

#14. Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives ...

Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed | 2021-08-31 ...

#15. FDA Grants Fast Track Designation to Silmitasertib for SHH ...

The FDA has granted fast track designation to the highly selective casein kinase 2 (CK2) inhibitor, silmitasertib (CX-4945), ...

#16. Clinical Trials Using Silmitasertib Sodium - National Cancer ...

NCI supports clinical trials that test new and more effective ways to treat cancer. Find clinical trials studying silmitasertib sodium.

#17. Senhwa gets DMC nod to progress trial of Covid-19 drug ...

Silmitasertib acts on the protein kinase CK2 pathway and is said to have high clinical potential to treat Covid-19. The CK2-inhibitor can ...

#18. Silmitasertib (CX-4945) | Casein Kinase 2 Inhibitor

Silmitasertib (CX-4945) induces cytotoxicity and apoptosis, and exerts anti-proliferative effects in hematological tumors by downregulating CK2 expression and ...

#19. Silmitasertib (CX-4945) - Casein Kinase inhibitor - Selleck ...

Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, ...

#20. CX-4945 (Silmitasertib) - CK2 - APExBIO

CX-4945 (Silmitasertib) is a potent and selective casein kinase 2 (CK2) inhibitor with IC50 value of 1 nM. It is ATP-competitive and can be taken orally [1] ...

#21. silmitasertib | Ligand page - IUPHAR/BPS Guide to ...

Comment: Silmitasertib (CX-4945) is a a potent and selective inhibitor of CK2 (casein kinase 2) [4-5]. CX-4945 is described in the same article as CX-5011 and ...

#22. CX-4945 (Silmitasertib) - CK2 inhibitor - AdooQ® Bioscience

CX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, ...

#23. Senhwa Biosciences - Silmitasertib - AdisInsight

Silmitasertib (CX 4945) is an orally-administered, small molecule, inhibitor of casein kinase II (CK2), being developed by Senhwa Biosciences, ...

#24. Silmitasertib (CX-4945) | 购买Casein Kinase 抑制剂 - Selleck ...

Silmitasertib (CX-4945)是有效的，选择性CK2(casein kinase 2)抑制剂，无细胞试验中IC50为1 nM,对Flt3, Pim1 和CDK1作用效果稍弱(细胞试验中没有活性)。

#25. Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial

Silmitasertib is a first-in-class small molecule drug that targets the CK2 pathway and acts as a CK2-inhibitor. It is safe and well-tolerated in ...

#26. 新藥Silmitasertib已獲衛福部緊急核准治療申請恩慈療法之新冠 ...

(6492)生華科-因應國內新冠肺炎疫情嚴峻，生華科新藥Silmitasertib(CX-4945)已於今日獲衛福部緊急核准治療申請恩慈療法之新冠肺炎重症患者。

#27. 生華科新冠藥物獲緊急核准陽明交大附醫啟動重症治療 - 蘋果日報

生華科Silmitasertib原為研發用以抗癌的市場首見小分子標靶新藥，Silmitasertib已經治療超過200位癌症病人，安全性無虞；同時Silmitasertib為口服劑型能 ...

#28. 《生醫股》生華科Silmitasertib 治療新冠中症患者二期臨床數據 ...

【時報-台北電】生華科(6492)Silmitasertib治療新冠肺炎中症患者二期臨床試驗數據已於2021 ISIRV-WHO大會發表，Silmitasertib治療組康復時間中位數6天 ...

#29. 生華科新藥證實可抑制冠狀病毒，將緊急啟動動物試驗

生華科21日表示，其新藥CK2抑制劑--Silmitasertib(CX-4945)，委由台灣國衛院冠狀病毒篩選平台，進行人類流感冠狀病毒體外試驗，試驗結果證實Silmitasertib具有良好抑制 ...

#30. Novel CK2 Inhibitor Silmitasertib Shows Promise in ...

Silmitasertib (CX-4945) is an oral small-molecule CK2 inhibitor that has exhibited preclinical antitumor activity and strong synergism with ...

#31. 生華科新冠藥物進二期臨床總座宋台生：已有藥廠接洽授權

生華科（6492）總經理暨執行長宋台生今（1）日表示，新藥Silmitasertib(CX-4945)已經在11月獲美國FDA核准進入兩項新冠人體臨床，終極目標是將開發中 ...

#32. Senhwa Presents Positive Initial Data from Phase 2 Clinical ...

Silmitasertib is a host-directed antiviral and an anti-inflammatory investigational therapy expected to be effective against emerging SARS-CoV-2 ...

#33. 此數據已獲選於2021年ISIRV-WHO大會大公開發表。 - 台股- 新聞

[公告] 生華科:本公司開發中新藥Silmitasertib治療新冠肺炎中症患者二期臨床試驗數據，相較對照組已達統計上顯著差異，此數據已獲選於2021年ISIRV-WHO ...

#34. [公告] 生華科:本公司新藥Silmitasertib(CX-4945)在美國治療 ...

[公告] 生華科:本公司新藥Silmitasertib(CX-4945)在美國治療新冠肺炎(COVID-19)中症二期人體臨床試驗已完成收案。公開資訊觀測站(2021-08-16 14:06:59).

#35. ‪#‎silmitasertib‬ - Explore | Facebook

生產新冠肺炎口服藥的生華科，今天傳來二期試驗的好消息。 接受Silmitasertib治療的中症病人，康復時間的中位數為6天， ...

#36. Senhwa Bio explores Silmitasertib for COVID-19 treatment

The scientists, knowing that CK2 is being upregulated by the virus, selected Silmitasertib (as the only first-in-class CK2 inhibitor ...

#37. 生華科武肺新藥二期臨床數據顯示可加速患者康復

生華科今日公告，該公司開發中的抗新冠肺炎藥物Silmitasertib（CX-4945），其治療中症患者二期臨床試驗數據摘要，已於今日的2021年國際流感和其他呼吸道 ...

#38. Senhwa Presents Positive Data from Phase 2 Trial of ...

Senhwa Biosciences presented positive efficacy and safety results from an investigator-initiated, Phase 2 clinical trial of Silmitasertib in ...

#39. Silmitasertib (CX-4945) in combination with gemcitabine and ...

Background: Silmitasertib (CX-4945), an oral small molecule inhibitor of casein kinase 2 (CK2), has exhibited preclinical antitumor activity and ...

#40. Small Molecule “Silmitasertib” Repurposed as Inhibitor of ...

Small Molecule “Silmitasertib” Repurposed as Inhibitor of Transforming Growth Factor Beta 1 for the Development of Therapeutics for Oral Submucous Fibrosis ...

#41. 生華科新冠二期臨床數據達標獲選ISIRV-WHO大會發表

生華科（6492）今天公告開發中抗新冠藥物Silmitasertib(CX-4945)治療中症患者二期臨床試驗初步數據分...

#42. Selleck Chemical LLC Silmitasertib (CX-4945) 2mg 1009820 ...

Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, ...

#43. Evaluating Safety, Pharmacokinetics and Clinical Benefit of ...

... clinical benefits of Silmitasertib 1000 mg BID dose in patients with moderate COVID-19. ... care with addition of Silmitasertib (allocation ratio 1:1).

#44. HY-50855-100mg | Silmitasertib [1009820-21-6] Biotrend

Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.

#45. 生華科新冠二期臨床數據達標獲選ISIRV-WHO大會發表 - 經濟日報

生華科（6492）今天公告開發中抗新冠藥物Silmitasertib(CX-4945)治療中症患者二期臨床試驗初步數據分...

#46. CK2 inhibition with silmitasertib promotes methuosis-like cell ...

The most recently developed CK2 inhibitor, silmitasertib (formerly CX-4945), has been tested in phase I/II trials for cholangiocarcinoma and ...

#47. A phase Ib/II study.,Journal of Clinical Oncology - X-MOL

312 Background: Silmitasertib (CX-4945), an oral small molecule inhibitor of casein kinase 2 (CK2), has exhibited preclinical antitumor ...

#48. 美國Banner Health選中生華科新藥治癒首位新冠患者

生華科（6492）新藥Silmitasertib (CX-4945)首次用於新冠肺炎治療，五天就讓美國新冠重症患者康復出院，負責執行這項緊急人體臨床試驗(eIND)的合作 ...

#49. Silmitasertib Gets Fast Track Status for Recurrent Sonic ...

The FDA has granted a fast track designation to the highly selective CK2 inhibitor silmitasertib as a potential therapeutic option for ...

#50. SILMITASERTIB - Inxight Drugs

Silmitasertib (CX-4945) is a potent and selective orally bioavailable small molecule inhibitor of Casein kinase II (CK2). The antiproliferative activity of ...

#51. CX-4945 (Silmitasertib) | Biorbyt

CX-4945 (Silmitasertib) · Catalog Number: orb180973 · About Us · A-Z Products · Popular Products · Help & Support.

#52. AIM Substance - Silmitasertib

Silmitasertib. Phase of research. Potential treatment - pre-clinical evidence. How it helps. Antiviral. Drug status.

#53. Senhwa reports positive data from Phase II trial of Covid-19 ...

Silmitasertib was found to be well-tolerated with a beneficial safety ... antiviral therapy, Silmitasertib, in moderate Covid-19 patients.

#54. FDA允许开展Silmitasertib治疗COVID-19患者的II期临床试验

生物制药公司Senhwa Biosciences今日宣布，已收到美国食品和药品监督管理局（FDA）肯定回复，将开始II期临床试验，以评估Silmitasertib治疗中 ...

#55. CX-4945 (Silmitasertib) | CK2a kinase inhibitor - Cellagen ...

... inhibitor of CK2a with an IC50 potency of 1 nM and Ki of 0.38 nM. [1, 2] In a p | CX-4945, CX 4945, CX4945, Silmitasertib, 1009820-21-6, CK2, Kinase.

#56. Senhwas Silmitasertib Receives US FDA Fast Track ...

Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, ...

#57. silmitasertib - BioWorld

The company's silmitasertib is the only clinical-stage inhibitor of CK2, a kinase recently identified by researchers as being hijacked by ...

#58. Silmitasertib (CX-4945) Price - AbMole BioScience

CX-4945 (Silmitasertib) is a potent small molecule protein kinase inhibitor that selectively binds to and inhibits the enzyme casein kinase II (CK2).

#59. 生華科Silmitasertib治療新冠中症患者二期數據已於2021 ISIRV ...

本公司Silmitasertib治療新冠肺炎中症患者二期臨床試驗. 數據已於2021 ISIRV-WHO大會發表，Silmitasertib治療組康復. 時間中位數6天，相較對照組14 ...

#60. Senhwa secures DMC approval to advance Phase II trial of ...

Senhwa Biosciences has announced that its oral drug, Silmitasertib, has received positive feedback from an independent Data Monitoring ...

#61. 《生醫股》生華科新藥Silmitasertib獲美FDA授予PRV門票

生華科(6492)開發中新藥Silmitasertib(CX-4945)用於新適應症兒童惡性腦瘤－髓母細胞瘤，正式獲得美國食品藥物監督管理局(FDA)授予「罕見兒科疾病 ...

#62. CX-4945 (Silmitasertib) from MyBioSource.com - Biocompare

MBS575013 (Silmitasertib) is a potent and selective inhibitor of CK2 ( casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to FIt3, ...

#63. 我们已经不再供应CX-4945 (Silmitasertib), ATP-competitive ...

我们已经不再供应CX-4945 (Silmitasertib), ATP-competitive CK2 protein kinase inhibitor (ab141350). 我们目前无法提供ab141350，抱歉给您带来不便。

#64. CX-4945 (Silmitasertib), inhibitor - MyBioSource

Buy CX-4945 (Silmitasertib), inhibitor (MBS386169) product datasheet at MyBioSource, Inhibitors.

#65. COVID-19抗病毒藥物治療案例分享

Compassionate use of silmitasertib for Patients with Severe COVID-19. Inclusion criteria. Supply: Silmitasertib (CX-4945 ; Senhwa) cap 200 ...

#66. Silmitasertib: Uses, Interactions, Mechanism of Action

Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With ...

#67. 藥劑部- 廠商專區 - 國立台灣大學醫學院附設醫院

藥劑部,,National Taiwan University Hospital,臺大醫院肇建於西元1895年，為國家級教學醫院，肩負教學、研究、服務三大任務。台大醫院網站提供醫療團隊、特色醫療 ...

#68. Silmitasertib

Silmitasertib. Silmitasertib is in phase I/II clinical trials by Senhwa for the treatment of cholangiocarcinoma combined with gemcitabine and cisplatin.

#69. Metabolic Plasticity of Cancer - 第 101 頁 - Google 圖書結果

Altogether, this may be heavily altered upon inhibition with very specific compounds like the CK2 inhibitor, silmitasertib, or alternatively some miRNAs ...

#70. Protein Kinase CK2 in Cancer Energetics | Oncology - Frontiers

Silmitasertib and CIGB-300, a cell-permeable peptide inhibitor of CK2 (25, 27), have been used in several clinical trials for the treatment ...

#71. 生華科(6492) | 即時-討論區-股市爆料同學會 - 理財寶

生華科(6492) 即時股價最新爆料，掌握股友們對生華科(6492) 即時股價、技術分析、新聞、股利、營收、每股盈餘(EPS)等個股資訊的第一手消息，還有眾多股市達人協助回答 ...

#72. Role of protein kinase CK2 in antitumor drug resistance

Consistently, the specific CK2 inhibitor CX-4945 (also known as silmitasertib) has been shown to suppress the DNA repair response to ...

#73. Senhwa Biosciences Announces Abstract Accepted for ...

Development is currently focused on two lead drug candidates, Silmitasertib (CX-4945) and Pidnarulex (CX-5461), both with novel mechanisms ...

#74. Ion and Water Transport in Cell Death - 第 2006 頁 - Google 圖書結果

... formation of giant vacuoles s-Triazine compound V6 CX-4945 (Silmitasertib) Zhang et al., 2021 Silva-Pavez et al., 2019 CX-4945 (Silmitasertib) Lertsuwan ...

#75. An Updated View on an Emerging Target: Selected Papers from ...

Silmitasertib (CX-4945) is an oral small molecule inhibitor of CK2, showing a selective anti-proliferative activity [14].

#76. 《財訊》620期-一次讀懂拜登經濟學 - 第 88 頁 - Google 圖書結果

... 但台灣這一部分可以和國際接軌,目前看有進展為生華,旗下用於武漢肺炎的新藥 Silmitasertib ,目前已經到 FDA 二期人體臨床試驗,股價也相對維持多頭姿態。

#77. 《財訊》612期-金牌操盤手　高檔選股絕學: 台股強彈進入下半場 搭對車再賺一波

Profile 生華科董事長:胡定吾總經理:宋台生資本額:7.45億元主要產品:市場首見新藥特色優勢: Silmitasertib具有對抗 COVID-19的潛力; Pidnarulex獲輝瑞欽點, ...

#78. Molecular Partners Provides Update from ACTIV ... - User Walls

No SAE related to Silmitasertib was reported.... #therapeutics#vaccine#FDA#iistudy#acceptance ...

#79. Molecular Partners Provides Update from ... - Stock Market

No SAE related to Silmitasertib was reported. ... Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19.

#80. Resonant_Therapy-Molecular_Biology_21 : ok33 - Internet ...

27 Silmitasertib 16m session - 16:02. 28 Sirolimus 16m session - 16:02. 29 Staph-Aureus SSL7 16m session - 16:02.